Veradermics is trading 7.35% down at $95.27, with no confirmed company-specific catalyst identified.
- No company-specific announcement dated August 24, 2026, was identified; the latest earnings and clinical updates were released August 11, 2026, not during today’s session.
- The Nasdaq Composite is down 0.54% and the S&P 500 0.25%, but broader weakness does not fully explain the decline.
- Earlier insider selling and post-lockup supply concerns may remain an overhang.